BiTEs targeting the MM-associated B-cell maturation antigen (BCMA) have been associated with very promising, albeit short-lived, efficacy signals raising hopes that they may provide the foundation for effective strategies against the immune-suppressive TME in MM [30,54,55,56,57,58] (Figure 2). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.